{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:25:37Z","timestamp":1793881537553,"version":"4.7.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,4,25]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Patients with SCD and severe organ damage can tolerate nonmyeloablative conditioning with no transplant-related mortality. Posttransplant cyclophosphamide prevents severe GVHD, increases engraftment, and improves the success rate for haploidentical HSCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016002972","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:40:29Z","timestamp":1492648829000},"page":"652-661","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT"],"prefix":"10.1182","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7167","authenticated-orcid":false,"given":"Courtney D.","family":"Fitzhugh","sequence":"first","affiliation":[{"name":"Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI),"},{"name":"Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6615","authenticated-orcid":false,"given":"Matthew M.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffani","family":"Taylor","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynona","family":"Coles","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Roskom","sequence":"additional","affiliation":[{"name":"Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI),"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delon","family":"Wilson","sequence":"additional","affiliation":[{"name":"Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI),"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wright","sequence":"additional","affiliation":[{"name":"Office of the Clinical Director, NIDDK, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Jeffries","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, Office of Biostatistics Research, NHLBI, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-2177","authenticated-orcid":false,"given":"Christopher J.","family":"Gamper","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Powell","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and NHLBI,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,4,19]]},"reference":[{"issue":"23","key":"2019111608504842200_B1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111608504842200_B2","doi-asserted-by":"crossref","first-page":"e0141706","DOI":"10.1371\/journal.pone.0141706","article-title":"Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia","volume":"10","author":"Fitzhugh","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2019111608504842200_B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"4 Suppl","key":"2019111608504842200_B4","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"5","key":"2019111608504842200_B5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","article-title":"Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now","volume":"118","author":"Hsieh","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111608504842200_B6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111608504842200_B7","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111608504842200_B8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Walters","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111608504842200_B9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1083-8791(03)00192-7","article-title":"Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia","volume":"9","author":"Iannone","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111608504842200_B10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1702518","article-title":"Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease","volume":"26","author":"van Besien","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111608504842200_B11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2007.08.050","article-title":"Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics","volume":"13","author":"Horwitz","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111608504842200_B12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2008.08.016","article-title":"Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease","volume":"14","author":"Krishnamurti","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019111608504842200_B13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12082","article-title":"Stem cell transplantation after reduced-intensity conditioning for sickle cell disease","volume":"90","author":"Matthes-Martin","year":"2013","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111608504842200_B14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111608504842200_B15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"2019111608504842200_B16","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia","volume":"2","author":"Walters","year":"1996","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2019111608504842200_B17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/bmt.2013.60","article-title":"Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model","volume":"48","author":"Fitzhugh","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2019111608504842200_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3540.3540","article-title":"Post-transplant cyclophosphamide and sirolimus are synergistic in preventing rejection and inducing stable mixed chimerism independently of regulatory T cells [abstract]","volume":"114","author":"Fitzhugh","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111608504842200_B19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/03630269009046967","article-title":"Sickle cell anemia and major organ failure","volume":"14","author":"Powars","year":"1990","journal-title":"Hemoglobin"},{"issue":"2","key":"2019111608504842200_B20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000167444","article-title":"Prognosis of the nephrotic syndrome in sickle glomerulopathy. A retrospective study","volume":"7","author":"Bakir","year":"1987","journal-title":"Am J Nephrol"},{"issue":"1","key":"2019111608504842200_B21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5414\/CNP58009","article-title":"Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival","volume":"58","author":"Abbott","year":"2002","journal-title":"Clin Nephrol"},{"issue":"4","key":"2019111608504842200_B22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2002-03-0948","article-title":"Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival","volume":"101","author":"Castro","year":"2003","journal-title":"Blood"},{"issue":"9","key":"2019111608504842200_B23","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111608504842200_B24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/apt.13347","article-title":"Liver injury is associated with mortality in sickle cell disease","volume":"42","author":"Feld","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2019111608504842200_B25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The acute chest syndrome in sickle cell disease: incidence and risk factors","volume":"84","author":"Castro","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2019111608504842200_B26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1182\/blood.V93.4.1164","article-title":"Bone marrow transplantation in adult thalassemic patients","volume":"93","author":"Lucarelli","year":"1999","journal-title":"Blood"},{"key":"2019111608504842200_B27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1196\/annals.1345.023","article-title":"Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group","volume":"1054","author":"La Nasa","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"2019111608504842200_B28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2019111608504842200_B29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111608504842200_B30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"issue":"3","key":"2019111608504842200_B31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood.V99.3.850","article-title":"Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait","volume":"99","author":"Kang","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111608504842200_B32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/sj.bmt.1703648","article-title":"High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation","volume":"30","author":"Nakamura","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2019111608504842200_B33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111608504842200_B34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbmt.2010.08.007","article-title":"Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients","volume":"17","author":"Reddy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111608504842200_B35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1703162","article-title":"Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing","volume":"28","author":"Nollet","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2019111608504842200_B36","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111608504842200_B37","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111608504842200_B38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/mt.2011.195","article-title":"Hematopoietic stem cell mobilization for gene therapy of adult patients with severe \u03b2-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects","volume":"20","author":"Yannaki","year":"2012","journal-title":"Mol Ther"},{"issue":"5","key":"2019111608504842200_B39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86252","article-title":"Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide","volume":"1","author":"Kanakry","year":"2016","journal-title":"JCI Insight"},{"issue":"12","key":"2019111608504842200_B40","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","article-title":"Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10\/10 human leukocyte antigen-matched unrelated and related donors","volume":"20","author":"Di Stasi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111608504842200_B41","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.4049\/jimmunol.162.5.2775","article-title":"Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation","volume":"162","author":"Powell","year":"1999","journal-title":"J Immunol"},{"issue":"11","key":"2019111608504842200_B42","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/01.tp.0000185299.72295.90","article-title":"Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism","volume":"80","author":"Powell","year":"2005","journal-title":"Transplantation"},{"issue":"7","key":"2019111608504842200_B43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111608504842200_B44","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"issue":"9","key":"2019111608504842200_B45","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.4049\/jimmunol.155.9.4179","article-title":"A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers","volume":"155","author":"Colson","year":"1995","journal-title":"J Immunol"},{"issue":"7","key":"2019111608504842200_B46","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.4049\/jimmunol.157.7.2820","article-title":"Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach","volume":"157","author":"Colson","year":"1996","journal-title":"J Immunol"},{"issue":"211","key":"2019111608504842200_B47","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"issue":"6","key":"2019111608504842200_B48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2019111608504842200_B49","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111608504842200_B50","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbmt.2013.02.010","article-title":"Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease","volume":"19","author":"Dallas","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111608504842200_B51","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111608504842200_B52","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111608504842200_B53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/bmt.2015.20","article-title":"Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study","volume":"50","author":"Esteves","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111608504842200_B54","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1590\/S1806-37132007000500015","article-title":"Sickle cell anemia-associated pulmonary arterial hypertension","volume":"33","author":"Machado","year":"2007","journal-title":"J Bras Pneumol"},{"issue":"3","key":"2019111608504842200_B55","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111608504842200_B56","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2012-03-414573","article-title":"Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study","volume":"120","author":"Raimondi","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111608504842200_B57","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111608504842200_B58","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2016.7","article-title":"Hematopoietic stem cell transplantation for homozygous \u03b2-thalassemia and \u03b2-thalassemia\/hemoglobin E patients from haploidentical donors","volume":"51","author":"Anurathapan","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2019111608504842200_B59","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment","volume":"62","author":"L\u00ea","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2019111608504842200_B60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjh.14015","article-title":"Improvement of medical care in a cohort of newborns with sickle-cell disease in North Paris: impact of national guidelines","volume":"173","author":"Couque","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/11\/652\/877041\/advances002972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/11\/652\/877041\/advances002972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T05:52:13Z","timestamp":1692769933000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/11\/652\/15629\/Cyclophosphamide-improves-engraftment-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,19]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,4,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016002972","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,19]]}}}